Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis

NCT ID: NCT06789315

Last Updated: 2025-01-23

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-20
• Study Completion Date: 2026-01-31

Brief Summary

Patients with acute alcoholic hepatitis will be identified based on national institute on alcohol abuse and alcoholism (NIAAA) will be identified, MELD score will be calculated, patents with MELD score between 20-35 will be randomized to two groups. Group A (intervention arm) will be receiving Mycofenolate mofetil at a dose of 750 mg twice daily and group B will be receiving steroid as per existing guidelines in a dose of 40 mg per day. Both the groups will be followed up for 90 days with assessment done at 4th, 7th and 28th day. Any significant event in addition will also be noted. Patients in group A will be also be monitored for development of complications like cytopenia due to Mycofenolate mofetil and infections will be monitored in both groups. Steroids will be stopped in the non-responders in group B based on Lille score at 4th and 7th day. The outcome variables of interest and to be measured are survival at 28 days and 90 days, clinical outcomes, including hospitalization and liver related outcomes.

Detailed Description

Study Design: Single-center, randomized control trial of 1 year duration.

Aim and Objective - To compare the efficacy and safety of Mycophenolate Mofetil (MMF) versus steroid therapy for the treatment of alcoholic hepatitis.

Hypothesis -

• MMF as a first line agent maybe associated with better 28 day and 90-day survival without increasing the risk of infection.

Study population: Patients > 18 years of age.Who are diagnosed as Alcoholic hepatitis based on NIAAA criteria.

• Study design: Randomized double blinded study.
• Study period: 1 year.
• Intervention: Intervention arm in the study will receive MMF at a dose of 750 mg twice daily for a period of 28 days, while the control arm will receive steroid at a dose of 40 mg for 28 days. However, based on Lille's score the decision to continue or discontinue steroid will be taken. In case of discontinuation of the drug in either group, they will be provided best medical care and nutrition as salvage therapy.
• Monitoring and assessment: History of all patients with special emphasis to alcoholic history will be taken. The diagnosis of alcoholic hepatitis is confirmed by NIAAA criteria. Liver biopsy will be done in clinically indicated cases. Patients will be classified into acute on chronic liver disease (ACLF) based on APASL criteria. Patients who are eligible for steroid therapy will be randomized to receive steroid or MMF based on computer software. Patients who are in MMF group will receive 750 mg twice daily of MMF. Patients who are in steroid group will receive 40 mg Prednisolone. The study is open label randomized control trial. Lilles score is calculated at 5th day to see for response.

Conditions

Alcoholic Hepatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

mycophenolate mofetil

Intervention arm in the study will receive MMF at a dose of 750 mg twice daily for a period of 28 days.

Group Type: EXPERIMENTAL

Mycophenolate Mofetil

Intervention Type: DRUG

MMF at a dose of 750 mg twice daily for a period of 28 days,

Steroid prednisolone

steroid at a dose of 40 mg for 28 days.

Group Type: ACTIVE_COMPARATOR

Prednisone

Intervention Type: DRUG

Prednisone at a dose of 40 mg for 28 days.

Interventions

Mycophenolate Mofetil

MMF at a dose of 750 mg twice daily for a period of 28 days,

Intervention Type: DRUG

Prednisone

Prednisone at a dose of 40 mg for 28 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adults aged 18-70 years.

2. Diagnosis of Alcoholic hepatitis based on NIAAA criteria

3. MELD 20-35

4. Willing to follow up

Exclusion Criteria

1. Patients with hepatic/ extra hepatic malignancies

2. Patients with contraindications to steroids

3. Patients who are critically ill and are admitted to the ICU

4. Patient who have severe extra hepatic organ failure

5. Patients who are HBsAg +, HIV+

6. If female of childbearing potential: known pregnancy, or unwilling to practice anticontraceptive measures

7. Patients who are on current treatment with prednisone and/or immunosuppressive me.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institute of Liver and Biliary Sciences, India

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Institute of Liver & Biliary Sciences

New Delhi, National Capital Territory of Delhi, India

Countries

India

Central Contacts

Dr Ananthu Narayan, MD

Role: CONTACT

ananthunarayansj@gmail.com

01146300000

Dr Shasthry SM, DM

Role: CONTACT

shasthry@gmail.com

01146300000

Facility Contacts

Dr Ananthu Narayan S J, MD

Role: primary

ananthunarayansj@gmail.com

01146300000

Other Identifiers

ILBS-Alcoholic Hepatitis-04

Identifier Type: -

Identifier Source: org_study_id